Vraylar vs Rexulti
A side-by-side look at two mental health medications advertised on TV. Informational only — not medical advice.
| US Vraylar | US Rexulti | |
|---|---|---|
| Generic name | cariprazine | brexpiprazole |
| Drug class | Atypical Antipsychotic | Atypical Antipsychotic |
| Treats | Bipolar disorder, schizophrenia, depression (add-on) | Major depression (add-on), schizophrenia, agitation in dementia |
| Category | Mental Health | Mental Health |
| Manufacturer | AbbVie | Otsuka/Lundbeck |
| Year approved | 2015 | 2015 |
| FDA warning | Black box warning | Black box warning |
| Est. TV ad spend | $200M | $170M |
| Common side effects | Movement disorders, Drowsiness, Restlessness, Weight changes | Weight gain, Restlessness, Drowsiness, Movement disorders |
Frequently asked questions
Is Vraylar or Rexulti better?
Neither is universally "better." Vraylar (cariprazine) and Rexulti (brexpiprazole) are both used for mental health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Vraylar and Rexulti?
Vraylar is a Atypical Antipsychotic made by AbbVie, while Rexulti is a Atypical Antipsychotic made by Otsuka/Lundbeck. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Vraylar has the larger estimated TV advertising budget of the two.